Ikarovec is an advanced medicine research and development organisation with a focus on treatments for common eye diseases using gene therapy technologies. It was formed as a spin-out company from Quethera in 2018, prior to its acquisition by Astellas Pharmaceuticals for access to Quethera’s proprietary gene therapy for glaucoma. Current ikarovec research portfolio includes treatments for diabetic macular oedema, age-related macular degeneration and ocular hypertension, which is a major risk factor for glaucoma. Seed funding is provided through UK Innovation and Science Seed Fund (UK I2S), LifeArc and Parkwalk Associates.
Norwich Research Park Innovation Centre